Rochester Clinical Research takes great pride in its contribution to Pfizer’s groundbreaking study on Zavzpret (zavegepant) migraine nasal spray, which has recently received FDA approval. This innovative treatment is the first of its kind designed to treat acute migraines in adults by acting as a calcitonin gene-related peptide (CGRP) receptor antagonist, effectively inhibiting CGRP from causing migraine attacks.
With over 40 million Americans suffering from migraines, this development is nothing short of a medical triumph. Zavzpret offers a compelling alternative to oral medication, which can be a daunting prospect for many migraine sufferers. The nasal spray’s rapid absorption by the nose means that it is much quicker acting than traditional oral medication, which must pass through the digestive system.
Throughout the study, the safety and tolerability of Zavzpret were thoroughly examined, and the nasal spray was found to be well-tolerated by participants. Moreover, those who received the medication experienced significant pain relief compared to those who were administered the placebo. In some cases, symptoms began to subside within just 15 minutes of treatment.
The approval of Zavzpret by the FDA is truly exciting news, as migraines can vary greatly in their severity and response to treatment. Given the sheer number of people affected by migraines daily, it is crucial to have multiple rapid treatment options available. Rochester Clinical Research remains dedicated to advancing the treatment of migraines by conducting further clinical trials.
Pfizer’s Press Release Link: